Investing.com - JPMorgan upgraded Recursion Pharmaceuticals (NASDAQ:RXRX) from Neutral to Overweight on Wednesday, while raising its price target to $11.00 from $10.00. The stock currently trades at ...

One analyst tracking the biotech upgraded her recommendation on its shares. She now believes that they rate a buy, rather than a hold.

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

U.S. prosecutors last week levied criminal hacking charges against 19-year-old U.K. national Thalha Jubair for allegedly being a core member of Scattered Spider, a prolific cybercrime group blamed for ...

If Java is not working in Windows 11/10, these solutions may help you troubleshoot the issue. Although, due to the lack of NPAPI support, Java applets stopped working in Microsoft Edge, Google Chrome, ...

Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7) SALT LAKE CITY, Aug. 05, 2025 ...

The last character of the text is cut off when rendering Mermaid diagrams using the “Recursive Sans” font. This issue only occurs when the block has only one line. It does not happen with blocks ...

June 10 (Reuters) - Recursion Pharmaceuticals (RXRX.O), opens new tab said on Tuesday it would lay off about 20% of its workforce as the biotech company tries to cope with an industry-wide funding ...